BioSpace News Archive

Kyttaro announces that it has entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and Company.

Truvic Medical, Inc., a wholly owned subsidiary of Imperative Care, Inc., today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Prodigy™ Thrombectomy System, designed for the treatment of peripheral vascular thrombus.

Alzamend Neuro, Inc. today announced that it contracted with Altasciences Clinical Kansas (“ Altasciences ”) and iResearch Atlanta, LLC (“iResearch”) to manage and conduct, respectively, its Phase IIA multiple ascending dose (“MAD”) study in patients with mild to moderate Alzheimer’s Disease (“Alzheimer’s”).

Vesigen Therapeutics, Inc. today announced the appointment of Paulash Mohsen as Chief Executive Officer.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 11:45 a.m. ET.

Lumos Pharma, Inc. announced this morning achievement of the 50% randomization milestone for our Phase 2 OraGrowtH210 Trial evaluating orally administered LUM-201.

Milestone Scientific Inc. reported that, following a successful trial and evaluation, it has commenced sales of its CompuFlo® Epidural and CathCheck™ Verification System disposables to a leading northeast medical center.

Biostage, Inc. announced that the U.S. Patent and Trademark Office has granted a new patent that extends its key intellectual property to cover regeneration and repair of the bronchus due to cancer, injury or birth defects.

Alliance Pharma announces that Patrick Bennett has been named Chief Executive Officer.

Altamira Therapeutics Ltd. announced that the International Journal of Molecular Sciences published a peer-reviewed paper confirming the Company’s positive research findings regarding the in vitro efficacy and safety of its drug-free nasal spray, Bentrio™, against the SARS-CoV-2 Delta variant.